20 ML emapalumab-lzsg 25 MG/ML Injection [Gamifant] — RxCUI 2665328
RxNorm drug concept · Semantic branded drug
RxCUI 2665328
Semantic branded drug · SBD
● Current RxNorm concept 7 FDA products
7 package NDCs
Snapshot Jul 14, 2026
What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.
🗂️ Key Facts
RxCUI2665328
Official name20 ML emapalumab-lzsg 25 MG/ML Injection [Gamifant]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as20 ML Gamifant 25 MG/ML Injection; Gamifant 500 MG in 20 ML Injection; Gamifant 500 MG per 20 ML Injection
FDA products mapped7
Package NDCs mapped7
Reported Medicaid activity (SDUD)29 prescriptions · 1 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026
📖 Skip the Codes — Read It in Plain English.
Our pharmacist-built guide to Emapalumab-lzsg Injection: what it is, how it’s used, side effects, and interactions.
📗 Our plain-language guide HelloPharmacist
- Gamifant is used to treat a rare but life-threatening condition called hemophagocytic lymphohistiocytosis — HLH for short — where the immune system goes into dangerous overdrive an...
- What exactly is Gamifant being used for?
- No, Gamifant is not a pill. It's given as an IV infusion — a slow drip directly into a vein — and it takes about one hour each time. It's always given in a clinical setting by a he...
- How is this medicine given — do I take a pill?
🕸️ Concept Web — How 20 ML emapalumab-lzsg 25 MG/ML Injection [Gamifa... Connects
One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept
20 ML emapalumab-lzsg 25 MG/ML Injection [Gamifant]
RxCUI 2665328 Semantic branded drug · SBD
Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.
-
Ingredients 2
The active substance itself — no strength, form, or brand attached yet.
-
Emapalumab
2104604IN -
Emapalumab-lzsg
2104603PIN
-
Emapalumab
-
Brand names 1
The same medicine's trade names. A brand name alone says nothing about strength or form.
-
Gamifant
2104612BN
-
Gamifant
-
Dose forms 9
The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.
-
Emapalumab Injection
2104610SCDF -
Emapalumab-lzsg Injection
2648899SCDFP -
Emapalumab Injectable Product
2104609SCDG -
Emapalumab-lzsg Injectable Product
2663362SCDGP -
Emapalumab Injection [Gamifant]
2104614SBDF -
Emapalumab-lzsg Injection [Gamifant]
2658510SBDFP -
Gamifant Injectable Product
2104615SBDG -
Injection
1649574DF - +1 more in this family
-
Emapalumab Injection
-
Clinical & branded drugs 3
Ingredient + strength + dose form. These are the concepts real FDA products actually carry.
-
20 ML emapalumab-lzsg 25 MG/ML Injection
2665325SCD -
Emapalumab-lzsg 25 MG/ML
2665324SCDC -
Emapalumab-lzsg 25 MG/ML [Gamifant]
2665327SBDC
-
20 ML emapalumab-lzsg 25 MG/ML Injection
Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.
🔀 Generic ⇄ Brand Crosswalk
The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.
Generic (Clinical) Concepts
-
20 ML emapalumab-lzsg 25 MG/ML Injection
SCD · 2665325 -
Emapalumab-lzsg 25 MG/ML
SCDC · 2665324 -
Emapalumab Injection
SCDF · 2104610 -
Emapalumab-lzsg Injection
SCDFP · 2648899 -
Emapalumab Injectable Product
SCDG · 2104609 -
Emapalumab-lzsg Injectable Product
SCDGP · 2663362
Brand-Name Concepts
-
Emapalumab-lzsg 25 MG/ML [Gamifant]
SBDC · 2665327 -
Emapalumab Injection [Gamifant]
SBDF · 2104614 -
Emapalumab-lzsg Injection [Gamifant]
SBDFP · 2658510 -
Gamifant Injectable Product
SBDG · 2104615 -
Gamifant
BN · 2104612
📦 FDA Products & Package NDCs
7 products · 7 package NDCs
7 package NDCs map to RxCUI 2665328 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
| Package NDC | Package | Brand / generic name | Labeler | Marketing start |
|---|---|---|---|---|
| 66658-0501-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-501-01) / 2 mL in 1 V... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2019-05-17 |
| 66658-0505-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-505-01) / 10 mL in 1... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2019-05-17 |
| 66658-0510-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-510-01) / 20 mL in 1... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2020-06-26 |
| 66658-0522-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-522-01) / 2 mL in 1 V... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2023-06-07 |
| 66658-0523-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-523-01) / 4 mL in 1 V... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2023-06-07 |
| 66658-0524-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-524-01) / 10 mL in 1... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2023-06-07 |
| 66658-0525-01 | 1 VIAL, SINGLE-USE in 1 CARTON (66658-525-01) / 20 mL in 1... | GAMIFANT | Swedish Orphan Biovitrum AB (publ) | 2023-06-07 |
Observed labelers:
Swedish Orphan Biovitrum AB (publ) (7)
— this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.
🧾 Billing Codes (HCPCS)
Medical billing codes (HCPCS "J-codes") that connect to this concept's packages — used mostly when a clinic or hospital bills for a drug it administers. Each code links to its full billing page.
| Code | Descriptor | Mapped packages | Sources |
|---|---|---|---|
| J9210 | Inj., emapalumab-lzsg, 1 mg | 3 | CMS |
⚠ A crosswalk is not coverage: an NDC↔HCPCS mapping does not guarantee any payer covers or pays the code. Always verify the current payer policy before billing.
🗃️ Sources & Limits
Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
- A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
- Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
- Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
- Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.
Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.